213 related articles for article (PubMed ID: 31651524)
1. Denosumab-treated Giant Cell Tumors of Bone: A Clinicopathologic Analysis of 35 Cases From the French Group of Bone Pathology.
Treffel M; Lardenois E; Larousserie F; Karanian M; Gomez-Brouchet A; Bouvier C; Le Loarer F; Aubert S; de Pinieux G; Audard V; Rios M; Sirveaux F; Vignaud JM; Gauchotte G; Marie B
Am J Surg Pathol; 2020 Jan; 44(1):1-10. PubMed ID: 31651524
[TBL] [Abstract][Full Text] [Related]
2. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
3. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
Kerr DA; Brcic I; Diaz-Perez JA; Shih A; Wilky BA; Pretell-Mazzini J; Subhawong TK; Nielsen GP; Rosenberg AE
Am J Surg Pathol; 2021 Jan; 45(1):93-100. PubMed ID: 32773532
[TBL] [Abstract][Full Text] [Related]
6. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
7. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
8. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
9. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
Gong LH; Liu WF; Ding Y; Zhang W; Yang YK; Yu F; Wong GQ; Huang XY; Niu XH
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):449-454. PubMed ID: 29886590
[No Abstract] [Full Text] [Related]
10. Histopathological response to denosumab in giant cell tumours of bone - A review of 11 cases.
Kumar R; Mallya V; Mandal S; Tomar R; Khurana N; Maini L
J Cancer Res Ther; 2023; 19(3):768-772. PubMed ID: 37470608
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
[TBL] [Abstract][Full Text] [Related]
12. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
13. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
14. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.
Rekhi B; Verma V; Gulia A; Jambhekar NA; Desai S; Juvekar SL; Bajpai J; Puri A
Pathol Oncol Res; 2017 Jan; 23(1):157-164. PubMed ID: 27722984
[TBL] [Abstract][Full Text] [Related]
16. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
18. Morphologic evaluation of the effect of denosumab on giant cell tumors of bone and a new grading scheme.
Erdogan KE; DevecI MA; Paydas S; Gonlusen G
Pol J Pathol; 2016; 67(4):392-397. PubMed ID: 28547968
[TBL] [Abstract][Full Text] [Related]
19. Blue lacy matrix in giant cell tumour of bone with or without denosumab therapy.
Toda Y; Ishihara S; Kawai A; Yoshida A
Virchows Arch; 2023 Jul; 483(1):125-129. PubMed ID: 36447097
[TBL] [Abstract][Full Text] [Related]
20. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
